Novel CAR T-Cell Therapies for Hematologic Malignancies

October 5, 2022 | 1 - 3 p.m. CT

Several CAR T-cell therapies have achieved durable responses in hematological malignancies, resulting in FDA approval of these products. Still, challenges remain to include “off-the-shelf” options and treatments for solid tumors, where the suppressive microenvironment is particularly problematic. Speakers during this session will review the current state of CAR T-cell therapies. They'll also provide updates on how CRISPR-based genome editing technologies are being applied to further understanding of T-cell function and to create novel T-cell products for patients. 

This session is free for ASGCT Members and $50 for non-members.

Registrants & ASGCT Members: Watch On Demand


Moderators: Daniela Bischof, PhD and Justin Eyquem, PhD
Indiana University School of Medicine, University of California, San Francisco

Lessons Learned on CAR T-Cells for Malignancies

Cliona Rooney, PhD
Texas Children's Hospital / Baylor College of Medicine

Novel CRISPR/Cas-Based Editing Approaches for Studying T-Cell Function

Julia Carnevale, MD
University of California San Francisco

Novel CRISPR/Cas Based Editing Approaches for Generating Engineered T Cells

Beau Webber, PhD
University of Minnesota

Thank You to Our Sponsor

Learn about sponsorship opportunities


ASGCT Policy Summit

Watch on demand through Oct. 23!

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.